# Poolbeg Pharma POLB 001 US patent assessment is going to plan

- Link: https://www.directorstalkinterviews.com/poolbeg-pharma-polb-001-us-patent-assessment-is-going-to-plan/4121021085
- Published: 2021-09-07T07:22:52+01:00
- Author: Giles

**[Poolbeg Pharma plc](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l)**(
[LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l)),
a clinical stage infectious disease pharmaceutical company with a capital light 
clinical model, has provided an update on the strengthening of its intellectual 
property (IP) position around lead product, POLB 001, a small molecule immunomodulator
for the treatment of severe influenza.

As detailed in the Admission Document, Poolbeg has a worldwide license for POLB 
001 and is developing a strong IP portfolio with patent protections in place covering
the use of the class of p38 MAP kinase (mitogen-activated protein kinase) inhibitors
for the treatment or prevention of severe influenza and hypercytokinaemia (or “cytokine
storm”). The Company continues to also evaluate POLB 001’s therapeutic uses beyond
severe influenza.

The US Patent and Trademarks Office examiner reviewing the patent application around
POLB 001 has indicated to the Company that the majority of the claims, including
the main claim are allowable. The main claim relates to the use of p38 MAP kinase
inhibitors as a class of compounds, including POLB 001, for the treatment of severe
influenza through modulation of the immune response. Poolbeg anticipates receiving
a formal patent grant in due course.

The European patent was granted prior to the IPO with claims to the treatment of
severe influenza, which is characterised by symptoms that persist or recur for more
than two days without signs of resolution, with a p38 MAP kinase inhibitor inhibiting
the release of pro-inflammatory mediators from endothelial cells and pro-inflammatory
cytokines from immune cells. This granted patent offers protection until 2037.

Assessment of the applications filed in other territories is ongoing.

> **Jeremy Skillington, PhD, CEO of Poolbeg Pharma said:**
> “Our US patent assessment is going to plan and we look forward to updating our
> shareholders when we receive confirmation of its grant. With the fast-growing 
> infectious disease market expected to exceed $250bn by 2025 and the current market
> for influenza already c. $800m, the protection of our intellectual property is
> very important. As stated in our AIM Admission Document upon listing, our intention
> is to continue to aggressively file patent applications to protect Poolbeg’s assets.”

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with
a capital light clinical model which aims to develop multiple products faster and
more cost effectively than the conventional biotech model. The Company, headquartered
in London, is led by a team with a track record of creation and delivery of shareholder
value and aspires to become a “one-stop shop” for Big Pharma seeking mid-stage products
to licence or acquire.

The Company is targeting the growing infectious disease market. In the wake of the
COVID-19 pandemic, infectious disease has become one of the fastest growing pharma
markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc, an industry leading infectious disease
and human challenge trials business, Poolbeg has access to knowledge, experience,
and clinical data from over 20 years of human challenge trials. The Company is using
these insights to acquire new assets as well as reposition clinical stage products,
reducing spend and risk. It already has a Phase II ready repositioned small molecule
immunomodulator for severe influenza and a portfolio of other exciting assets. The
Company plans to broaden this portfolio further going forward and is in active discussions
with AI data analysis platforms to help accelerate the power of its human challenge
model data and biobank.

Share on:
